Q-omics provides the consensus-scored SUZ12 profile across patient tissues and cancer cell-line models. SUZ12 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SUZ12 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SUZ12 protein abundance shows 26,208 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where SUZ12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUZ12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUZ12 survival associations across molecular data types. SUZ12 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUZ12 RNA expression–survival associations across cancer types. High SUZ12 expression shows unfavorable associations in ACC, MESO, LIHC and KICH, but favorable associations in KIRC and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SUZ12 RNA expression.
This table summarizes SUZ12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SUZ12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUZ12 shows higher tumor expression in HNSC, BLCA, STAD, LIHC, LUAD and BRCA. The HNSC box plot shows higher SUZ12 RNA expression in tumor versus normal tissue (log2 FC = +1.003, t-test p < 0.001).
This table shows molecular features associated with SUZ12 in patient tissues and cancer cell lines. In patient samples, SUZ12 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SUZ12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
